Olix "MCurex Signs MOU with GC녹십자 for mRNA Vaccine and Therapeutics Development"

[Asia Economy Reporter Hyunseok Yoo] MQUREX, a subsidiary of Olix, announced on the 11th that it signed a memorandum of understanding (MOU) with GC Green Cross (CEO Euncheol Heo) on the 10th to develop mRNA vaccines and therapeutics for respiratory infectious diseases.

MQUREX has research and development capabilities for mRNA vaccines and therapeutics based on mRNA platform technology. GC Green Cross possesses abundant clinical resources and experience accumulated over more than 50 years, as well as solid expertise in finished pharmaceutical manufacturing.

Seonwoo Hong, CEO of MQUREX, stated, "Whenever epidemic respiratory infectious diseases such as MERS, SARS, and COVID-19 threaten the world, the demand for vaccines and therapeutics increases explosively. However, existing vaccines and therapeutics require a long development period, making it difficult to quickly contain disease spread." He added, "With the proven short development time and excellent efficacy of mRNA vaccines during the recent COVID-19 crisis, the localization of mRNA vaccines and therapeutics has become an essential task for Korea to secure sovereignty over mRNA vaccines and therapeutics in the future." He continued, "The MOU signed with GC Green Cross this time will serve as an opportunity to significantly shorten the time required to successfully localize mRNA vaccines and therapeutics."

MQUREX is a subsidiary established by Olix, a company developing third-generation innovative drugs based on RNA interference technology, to develop mRNA vaccines and therapeutics. It has recruited mRNA experts who participated in the development of the ‘mRNA 5’-Capping’ technology applied to a global pharmaceutical company's COVID-19 mRNA vaccine currently administered in the United States and Europe as research directors and scientific advisory board (SAB) members.

This content was produced with the assistance of AI translation services.